Table 1.
Summary characteristics of patients with CBS seen during March 2019 to February 2020 and during September 2020 to August 2021.
| Characteristics | March 2019–February 2020 (N = 156) | September 2020–August 2021 (N = 155) |
|---|---|---|
| Age at time of letter | 76 [IQR 63.5–87] | 77 [IQR 64–85] |
| Clinic letter specialty | ||
| A&E | 1 (0.6%) | 3 (1.9%) |
| Cataract | 5 (3.2%) | 0 |
| External | 2 (1.3%) | 9 (5.8%) |
| General ophthalmology | 5 (3.2%) | 3 (1.9%) |
| Genetics | 3 (1.9%) | 2 (1.3%) |
| Glaucoma | 24 (15.4%) | 26 (16.8%) |
| Medical retina | 85 (54.5%) | 78 (50.3%) |
| Neuro-ophthalmology | 13 (8.3%) | 9 (5.8%) |
| Optometry | 2 (1.3%) | 11 (7.1%) |
| Orthoptics | 1 (0.6%) | 1 (0.6%) |
| Paediatrics | 4 (2.6%) | 0 |
| Strabismus | 5 (3.2%) | 0 |
| Uveitis | 6 (3.8%) | 7 (4.5%) |
| Vitreoretinal | 7 (4.5%) | 6 (3.9%) |
| Sex | ||
| Male | 55 (35.2%) | 63 (40.6%) |
| Female | 101 (64.8%) | 92 (59.4%) |
| Ethnicity | ||
| Afro-Caribbean | 14 (9.0%) | 13 (8.4%) |
| Caucasian | 88 (56.4%) | 82 (52.9%) |
| Asian | 14 (9.0%) | 13 (8.4%) |
| Not stated | 40 (25.6%) | 47 (30.3%) |
| Age of onset of CBS | 76 [IQR 60.5–86] | 77 [IQR 63–85] |
| BCVA at time of onset | ||
| Better eye | [IQR 0.3–1.78] | 0.8 [IQR 0.4–1.48] |
| Worse eye | 1.8 [IQR 0.9–2.3] | 1.9 [IQR 1.0–2.3] |
| Registered SI or SSI | 67 (42.9%) | 43 (27.7%) |
| Reporting HCP | ||
| Consultant ophthalmologist | 59 (37.8%) | 53 (34.2%) |
| Consultant neurologist | 2 (1.3%) | 0 |
| General practitioner | 1 (0.6%) | 0 |
| Not known | 1 (0.6%) | 2 (1.3%) |
| Ophthalmologist in training | 81 (51.9%) | 67 (43.2%) |
| Specialist nurse | 1 (0.6%) | 0 |
| Optometrist | 10 (6.4%) | 32 (20.6%) |
| Orthoptist | 1 (0.6%) | 1 (0.6%) |
A&E, accident and emergency; BCVA, best corrected visual acuity; CBS, Charles Bonnet syndrome; HCP, healthcare professional; IQR, interquartile range; SSI, severely sight impaired; SI, sight impaired.